{"id":607704,"date":"2026-09-06T13:58:22","date_gmt":"2026-09-06T13:58:22","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/607704\/"},"modified":"2026-09-06T13:58:22","modified_gmt":"2026-09-06T13:58:22","slug":"if-youd-invested-in-moderna-mrna-stock-5-years-ago-heres-how-much-youd-have-today-hint-youd-be-disappointed-but-not-if-you-bought-it-1-year-ago","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/607704\/","title":{"rendered":"If You&#8217;d Invested in Moderna (MRNA) Stock 5 Years Ago, Here&#8217;s How Much You&#8217;d Have Today (Hint: You&#8217;d Be Disappointed &#8212; But Not If You Bought It 1 Year Ago.)"},"content":{"rendered":"<p>Moderna (<a href=\"https:\/\/www.fool.com\/quote\/nasdaq\/mrna\/\" class=\"font-bold hover:underline\" rel=\"nofollow noopener\" target=\"_blank\">MRNA<\/a> -2.23%) is famous for developing vaccines using mRNA technology (thus, its ticker symbol) &#8212; including its highly popular COVID-19 vaccine a few years ago. Enthusiasm over that vaccine helped propel the stock some 434% in 2020 and another 143% in 2021. Wow, right?<\/p>\n<p>But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged annual losses over that period &#8212; enough to turn a single $10,000 investment in early September 2021 into just $3,792 in early September 2026. Ouch!<\/p>\n<p><img alt=\"A bunch of hypodermic needles against a glowing yellow background.\" fetchpriority=\"high\" width=\"880\" height=\"623\" decoding=\"async\" data-nimg=\"1\" class=\"h-auto max-w-full rounded object-contain\" style=\"color:transparent\"   src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/09\/1788703102_359_.jpeg\"\/><\/p>\n<p class=\"caption\">Image source: Getty Images.<\/p>\n<p>However, the story doesn&#8217;t end there. What if you bought into the <a href=\"https:\/\/www.fool.com\/investing\/stock-market\/market-sectors\/healthcare\/biotech-stocks\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">biotech stock<\/a> with $10,000 just one year ago? Your stake would now be worth&#8230; $62,344. The stock has surged more than 500% over the past year!<\/p>\n<p><img alt=\"Moderna Stock Quote\" loading=\"lazy\" width=\"64\" height=\"64\" decoding=\"async\" data-nimg=\"1\" class=\"w-full flex-none object-contain\" style=\"color:transparent\"  src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/09\/1788703102_74_.png\"\/><\/p>\n<p>Today&#8217;s Change<\/p>\n<p>(-2.23%) $-3.32<\/p>\n<p>Current Price<\/p>\n<p>$145.55<\/p>\n<p>Key Data Points<\/p>\n<p>Market Cap<\/p>\n<p>$58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.<\/p>\n<p>Day&#8217;s Range<\/p>\n<p>$141.52 &#8211; $154.69<\/p>\n<p>52wk Range<\/p>\n<p>$22.28 &#8211; $176.66<\/p>\n<p>Volume<\/p>\n<p>15M<\/p>\n<p>Avg Vol<\/p>\n<p>15.6M<\/p>\n<p>Gross Margin<\/p>\n<p>12.57%<\/p>\n<p>The reason why is rather understandable: Moderna has been making some auspicious announcements. For starters, it has received regulatory approval for its updated COVID-19 vaccines. More intriguingly, it has also <a href=\"https:\/\/www.fool.com\/investing\/2026\/08\/19\/why-moderna-stock-skyrocketed-today\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">reported strong clinical trial results<\/a> for its drug to treat melanoma, a form of skin cancer (the drug was developed in partnership with Merck). A potential vaccine against cancer is a big deal, obviously, and Moderna co-founder and board chair Noubar Afeyan has suggested that this vaccine could be a springboard for vaccines against kidney, bladder, and lung diseases, among other conditions.<\/p>\n<p>Given all that, should you invest in Moderna now? Well, maybe. The company has been posting net losses instead of gains over the past few years, which isn&#8217;t attractive. However, it also has far more cash than debt, which is promising. Another plus is Moderna&#8217;s proprietary knowledge and technology, which isn&#8217;t easy for a rival to duplicate. It has dozens of treatments in its pipeline, too.<\/p>\n<p><a href=\"https:\/\/www.fool.com\/investing\/2026\/08\/20\/modernas-comeback-is-finally-taking-shape-and-ther\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">Given Moderna&#8217;s great promise<\/a>, I think it&#8217;s reasonable to <a href=\"https:\/\/www.fool.com\/investing\/2026\/08\/30\/is-it-too-late-to-buy-moderna-stock-after-its-127\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">buy a few shares<\/a> now &#8212; or wait and hope for a pullback. Research it further first, of course.<\/p>\n<p><a href=\"https:\/\/www.fool.com\/author\/1283\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">Selena Maranjian<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Moderna. The Motley Fool has a <a href=\"https:\/\/www.fool.com\/legal\/fool-disclosure-policy\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">disclosure policy<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Moderna (MRNA -2.23%) is famous for developing vaccines using mRNA technology (thus, its ticker symbol) &#8212; including its&hellip;\n","protected":false},"author":2,"featured_media":607705,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,85,46],"class_list":["post-607704","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/607704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=607704"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/607704\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/607705"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=607704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=607704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=607704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}